Natriuretic Agents

• 

  Subject Areas on Research

  • A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial. 
  • Acute decompensated heart failure: update on new and emerging evidence and directions for future research. 
  • Acute heart failure: perspectives from a randomized trial and a simultaneous registry. 
  • Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. 
  • Atrial natriuretic hormone, vessel dilator, long-acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of CRH, corticotropin, and cortisol. 
  • Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. 
  • Brain natriuretic peptide improves long-term functional recovery after acute CNS injury in mice. 
  • Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. 
  • Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 
  • Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. 
  • Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States. 
  • Effect of nesiritide in patients with acute decompensated heart failure. 
  • Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). 
  • Efficacy and safety of nesiritide in patients with acute decompensated heart failure. 
  • Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). 
  • Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. 
  • Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. 
  • Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 
  • Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. 
  • Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. 
  • Mode of death and hospitalization from the Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes. 
  • Nesiritide in acute decompensated heart failure. 
  • Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. 
  • Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). 
  • Perioperative nesiritide and possible renal protection in patients with moderate to severe kidney dysfunction. 
  • Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. 
  • Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. 
  • Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. 
  • Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. 
  • Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. 
  • Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). 
  • Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). 
  • Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). 
  • Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. 
  • The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). 
  • The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. 
  • Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. 
• 

  Keywords of People

  • James, Michael Lucas, Associate Professor of Anesthesiology, Anesthesiology, Neuroanesthesia
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology